1. Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study.
- Author
-
Scherneck, Stephan, Grupe, Katharina, Schlinke, Natalie, Beck, Evelin, Weber-Schoendorfer, Corinna, and Schaefer, Christof
- Subjects
- *
METFORMIN , *HEALTH outcome assessment , *MEDICATION safety , *FIRST trimester of pregnancy , *COHORT analysis , *PHYSIOLOGY ,PREGNANCY complication risk factors - Abstract
Highlights • largest monocentric cohort study on metformin safety during the first trimester. • 336 pregnancies with metformin exposure and 1011 matched controls. • no increase in major birth defects and spontaneous abortions. • no distinct pattern of major birth defects. Abstract The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy. We conducted an observational cohort study comparing pregnancies with metformin treatment during the first trimester with non-exposed women matched for BMI and year of enrolment. Pregnancies were prospectively ascertained in the German Embryotox pharmacovigilance database between 2004 and 2014. The study sample included 336 pregnancies with metformin exposure for PCOS and fertility disorders (56.8%), diabetes (25.9%) and insulin resistance (14.9%) and 1011 matched controls. Independent of the treatment indication, neither the rate of major birth defects (OR adjusted 0.58, 95% CI 0.3–1.3) nor of spontaneous abortions (HR adjusted 0.95, 95% CI 0.6–1.5) was significantly increased among metformin exposed. Our study supports the evidence that metformin does not carry a developmental risk for the fetus when used during the first trimester. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF